Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Conditions
Interventions
Ramucirumab
Pembrolizumab
Locations
22
United States
Yale University School of Medicine
New Haven, Connecticut, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Florida Cancer Specialists and Research Institute
St. Petersburg, Florida, United States
Tennessee Oncology PLLC
Chattanooga, Tennessee, United States
Sarah Cannon Research Institute SCRI
Nashville, Tennessee, United States
Tennessee Oncology PLLC
Nashville, Tennessee, United States
Start Date
July 29, 2015
Primary Completion Date
August 31, 2018
Completion Date
April 12, 2022
Last Updated
July 31, 2024
NCT07164313
NCT06996782
NCT07190248
NCT06305754
NCT07100080
NCT07195695
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions